[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

3 clusters · 14 sources · 14 days · First seen · Last updated

Samsung Biologics expansion and PolyPeptide acquisition

Overview

Samsung Biologics has launched a public tender offer to acquire the Swiss-based peptide contract development and manufacturing organization (CDMO), PolyPeptide Group, through its subsidiary Samsung Peptide AG. The offer is set at CHF 44.31 per share in cash, representing a 40% premium over the closing price on April 10, 2026. If all outstanding shares are tendered, the total transaction value will reach approximately CHF 1.46 billion.

The PolyPeptide Group board has unanimously recommended the offer, supported by a fairness opinion from IFBC AG. The largest shareholder, Draupnir Holding B.V., which holds approximately 55.65% of shares, has committed to tendering its entire stake. To finalize the acquisition, Samsung Biologics must secure a minimum acceptance threshold of 66.67% of issued shares and obtain necessary regulatory approvals. The tender offer period is scheduled to run from September 15 to October 12, 2026. Following a successful tender, the company intends to pursue a squeeze-out of minority shareholders and delist PolyPeptide Group from the SIX Swiss Exchange.

This acquisition is funded by a previously announced 3.009 trillion KRW rights offering. Approximately 2.71 trillion KRW is allocated to the PolyPeptide transaction to diversify Samsung Biologics’ portfolio into high-growth peptide therapeutics, such as GLP-1 medications for obesity and diabetes. The remaining 295 billion KRW will support the expansion of the company’s second bio-campus in Songdo, Incheon, through the construction of plants 6, 7, and 8 to increase global antibody production capacity to 1.385 million liters.

Entities

Samsung Biologics · Polypeptide Group · Shin Yu-yeol · Songdo · Songdo Bio Campus II

Claims

What the coverage asserts, and how many sources carry each claim.

Timeline

  1. 18 days ago

    [BUSINESS] 5 sources
    Samsung Biologics launches CHF 1.46 billion tender offer for PolyPeptide Group

    Samsung Biologics has initiated a CHF 1.46 billion tender offer to acquire Swiss CDMO PolyPeptide Group, aiming to expand its capabilities into peptide-based therapeutics.

  2. 22 days ago

    [BUSINESS] 10 sources
    Samsung Biologics to raise 3 trillion won for PolyPeptide Group acquisition

    Samsung Biologics is raising 3 trillion won through a rights offering to acquire Swiss peptide maker PolyPeptide Group and expand its Songdo Bio Campus to boost global CDMO capacity.

  3. about 1 month ago

    [BUSINESS] 2 sources
    Lotte Biologics consolidates operations at new Songdo Bio Campus

    Lotte Biologics has consolidated its Korean operations at the new Songdo Bio Campus, aiming for commercial production next year through a dual-site strategy with its Syracuse, U.S. facility.

Sources

aijourn.com · biotech-investments.com · biz.heraldcorp.com · bosa.co.kr · jnilbo.com · joongboo.com · koreaherald.com · kosmo.com.my · kyeonggi.com · techholic.co.kr · tfmedia.co.kr · thebionews.net · tokenpost.kr · vir.com.vn

This summary has been updated 4 times: see revision history